World Continence Week 2019

Fifteen years ago, Mr Arun Sahai received funding from The Urology Foundation to look at the possibility of using Botox to treat patients with Overactive Bladder (OAB). He ran the world’s first ever level 1 double blind placebo controlled trial of Botox as a treatment for idiopathic OAB.

His TUF-funded work now means that millions of people across the globe have access to Botox to treat OAB, one of urology’s most debilitating diseases.

OAB can ruin lives

Overactive Bladder (OAB) affects 1 in 8 people, which is more people than diabetes, asthma, and osteoporosis and, although it can ruin a life, it’s rarely spoken about and few people have heard of it.

If a person has OAB, they cannot hold their bladder. It means that they could find themselves rushing to the toilet at any moment of the day.

The fear of not being able to find the toilet in time leaves some patients housebound, whilst for others it has a dramatic impact on work and family life. OAB can completely dominate a life.

Celebrating 15 years of life-changing treatment

Mr Arun Sahai is TUF researcher who used TUF’s funding to show that Botox, one of the most deadly poisons on the planet, can be used to effectively treat OAB.

For those patients who don’t respond to drug treatments, complex surgery was the only to treat OAB. But, thanks in part to Arun’s research, Botox injections are now used across the world to give patient’s control of their bladder again.

You shouldn’t have to suffer with OAB

If you find it hard to control your bladder, don’t suffer in silence. Go and see your GP because, thanks to TUF research, there are treatments that are readily available to you!

If you or someone you know has benefited from Botox injections for OAB, celebrate with us by using #Botox15. Together we can share a message of hope for OAB patients everywhere.

Kidney

Read more

Bladder

Read more

Prostate

Read more

Male reproductive organs

Read more